Predict your next investment

Corporation
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
dkfz.de

See what CB Insights has to offer

Investments

1

Partners & Customers

5

About Deutsches Krebsforschungszentrum

Deutsches Krebsforschungszentrum is a cancer research center. It develops approaches to make tumor diagnosis more precise and treatment of cancer patients more successful.

Deutsches Krebsforschungszentrum Headquarter Location

Neuenheimer Feld 280

Heidelberg, 69120,

Germany

+49 06221422995

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Deutsches Krebsforschungszentrum

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Deutsches Krebsforschungszentrum in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Deutsches Krebsforschungszentrum Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Deutsches Krebsforschungszentrum Rank

Latest Deutsches Krebsforschungszentrum News

Fraunhofer: Researchers plan to use quantum computer in development of cancer treatments

Aug 24, 2021

As a partner of the Fraunhofer Competence Network Quantum Computing, the German Cancer Research Center (DKFZ) is planning to use the quantum computer in Ehningen, Baden-Württemberg, to develop individually effective cancer treatment methods in the future. Cancer patients’ medical records can often comprise up to 100 terabytes of individual — and usually very heterogeneous — data, including blood and tumor values, personal indicators, sequencing and treatment data, and much more besides. Up to now, it has been virtually impossible to use this wealth of information efficiently due to a lack of appropriate processing mechanisms. As a result, the possibility of using promising personalized treatment approaches remains purely theoretical for many cancers, and patients are still receiving standard treatments. Now, the German Cancer Research Center (DKFZ) in Heidelberg is planning to use quantum computing to drive forward research in this area: “We want to explore how we can systematically process and use this heterogeneous data with the aid of a quantum computer, so that we can identify new and more targeted options for patients who do not respond so well to immunotherapies. Ultimately, we are asking which patient can benefit from which treatment and how,” says Dr. Niels Halama, Head of Department of Translational Immunotherapy at the German Cancer Research Center (DKFZ) and Senior Physician at the German National Center for Tumor Diseases. Linked to this topic are some applied research questions: Which signaling cascades and biological processes play a role in the disease? How can we use these to select a treatment on an individual basis? What kinds of problems actually lend themselves to being solved by quantum computers? From a simulator to a real quantum computer The DKFZ team has already worked out the mathematical principles and carried out some initial work using other globally available systems and simulators. According to Halama, however, there is a huge difference between working on a simulator with perfect qubits and working on a real quantum computer such as IBM Q System One in Ehningen. It is only with the latter that you can see how stable things are at a certain level of complexity, where the pitfalls are and what is possible. The researchers now want to use the Ehningen system to further develop and flesh out their ideas via an application-oriented approach. The aim is to find out which algorithms are suitable for processing the information in question and how they can be adapted or redeveloped as necessary — but also how, for example, error corrections can be optimized further. The DKFZ team is still looking for more cooperation partners from various fields of research and industry to enable an interdisciplinary investigation into the possibilities that quantum computing offers in the area of new cancer treatment approaches. “We are very pleased to have DKZF as a collaborative partner,” said Prof. Raoul Klingner, Director of Research Management and Governance at the Fraunhofer-Gesellschaft. “The use of quantum computing in a field as complex and significant as personalized cancer therapy highlights the potential that quantum computing offers for medicine and numerous other industries.” Data protection, speed and flexibility are key criteria For Halama, there are three important criteria when working with the quantum computer: data protection, speed and flexibility. The scientists are still working with test data at the moment, but when real patient data is used in the future, “it will be very advantageous that the Ehningen quantum computer operates under German data protection legislation and that the data remains on site,” says the physician. The speed of calculations, which could make quantum computing superior to conventional computing in the future, is another key criterion because — when it comes to cancer patients — every day counts and decisions need to be made quickly. As quantum processors can process data in parallel rather than in succession, they have the potential to analyze huge volumes of data in a fraction of the time that normal computers require. According to Halama, the flexible monthly ticket model that the Fraunhofer Competence Network Quantum Computing offers to its partners is also an important factor. “It allows us, as an academic institution, to use the system flexibly as and when needed without having to invest huge sums over a long period,” he says. “Furthermore, Fraunhofer is an important scientific partner for us and our collaboration allows us to bridge the gap between theoretical and applied research for the benefit of the patient.” About the DKFZ With over 3000 employees, the German Cancer Research Center (DKFZ) is the largest biomedical research institution in Germany. Over 1300 scientists at the DKFZ are studying how cancer develops, recording cancer risk factors and looking for new strategies to prevent people from getting cancer. They are developing new methods that can be used to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ Cancer Information Service (KID) provides patients, members of the public and specialists with individual responses to all questions relating to cancer. Together with partners from university hospitals, the DKFZ runs the German National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children’s Cancer Center (KiTZ) in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. The combination of excellent university medicine and the high-quality research of a Helmholtz Center at the NCT and DKTK sites plays a key role in transferring promising approaches from cancer research to hospital environments and thus improving the chances of cancer patients. The DKFZ is 90 percent financed by the German Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg, and is a member of the Helmholtz Association of German Research Centers. This article was first published on August 10 by Fraunhofer.

Deutsches Krebsforschungszentrum Investments

1 Investments

Deutsches Krebsforschungszentrum has made 1 investments. Their latest investment was in Apogenix as part of their Unattributed on January 1, 2012.

CBI Logo

Deutsches Krebsforschungszentrum Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/5/2012

Unattributed

Apogenix

$9.62M

Yes

Date

1/5/2012

Round

Unattributed

Company

Apogenix

Amount

$9.62M

New?

Yes

Co-Investors

Sources

Deutsches Krebsforschungszentrum Partners & Customers

5 Partners and customers

Deutsches Krebsforschungszentrum has 5 strategic partners and customers. Deutsches Krebsforschungszentrum recently partnered with Datameer, and Fujitsu on June 6, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

6/21/2016

Partner

Datameer, and Fujitsu

United States, and Japan

German Cancer Research Center Tackles Cancer With Datameer Modern BI Platform

The German Cancer Research Center , the largest biomedical research institute in Germany , collaborated with Datameer and Fujitsu to deploy Fujitsu for Hadoop , a powerful and scalable server cluster that integrates Datameer 's analytic platform .

3

10/15/2014

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/5/2014

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

2/4/2014

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/8/1999

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/21/2016

10/15/2014

5/5/2014

2/4/2014

6/8/1999

Type

Partner

Partner

Partner

Partner

Licensee

Business Partner

Datameer, and Fujitsu

Country

United States, and Japan

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

German Cancer Research Center Tackles Cancer With Datameer Modern BI Platform

The German Cancer Research Center , the largest biomedical research institute in Germany , collaborated with Datameer and Fujitsu to deploy Fujitsu for Hadoop , a powerful and scalable server cluster that integrates Datameer 's analytic platform .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.